CD19 and non-Hodgkin lymphoma: The complete remission (CR) rate in patients with R/R B-cell acute lymphoblastic leukemia (B-ALL), who received CD19 CAR T-cell therapies, is approximately 90%, while it is only 50% in patients with R/R B-cell NHL (B-NHL) (4–6).